Next Phase Newsletter

A family office located in New York makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life sciences and healthcare venture capital firm founded in 2014 is looking for global investment opportunities. The firm’s LPs include a pharma company and a government-owned fund of funds. The firm is currently allocating out of its $35M fund and actively seeking investment opportunities. The firm will typically participate in Seed to Series B rounds with initial sizes of investment ranging from $0.5M to $2.5M, and will earmark $1-3M for follow-on investments. The firm invests globally.

The firm is looking for companies with groundbreaking science and technology, and invests broadly across therapeutics, medical devices, diagnostics, and healthcare IT. The firm’s strongest expertise lies in therapeutics and they have invested the most in this sector. The firm will consider any asset from pre-clinical to phase II. The firm is open to all indications but is more selective when reviewing companies in overcrowded indications such as oncology.

The firm seeks innovative, high growth potential companies led by strong management teams, particularly with strong scientific expertise. The firm prefers to lead or co-lead investment rounds, especially if they are participating in Seed to Series A. They are also open to co-investing alongside other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group founded by several Chinese medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel, pre-A, Series A, and B rounds. The group seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success.

The group is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. .

The group heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at Guoqian so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A new VC firm founded in 2017 and based in the Mid-Atlantic region of the USA is actively looking for post-seed investment opportunities in which the firm’s partners can contribute significant value. The size of investment will vary on a case-by-case basis. Currently, the firm will only consider companies that are based in the USA.

The firm is most interested in medical devices and healthcare IT/digital health/AI in healthcare start-up companies with a unique, high-growth potential product or technology. The firm is highly interested in surgical devices that can dramatically improve outcomes in healthcare systems. Ideally, these companies should have broad IP protection and have existing first paying customers. The firm will not consider opportunities in the therapeutics sector.

The firm will evaluate investment opportunities based on a proprietary scoring model, which includes the company’s market size/niche, growth potential, management team, exit potential, etc. The firm will expect to see management teams with strong expertise in their company’s relevant sectors, as well as a strong business model. The firm will always take a board seat and one of the firm’s general partners will act as an entrepreneur-in-residence (EIR), taking an active role by serving as an advisor and providing project-specific expertise. The firm can act as the lead investor or co-invest with other funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Boston-based venture capital firm that raised a fund in 2017 makes early stage equity investments of about $10-15 million, and can either lead investments or co-invest. The firm will consider investment opportunities worldwide.

The firm invests primarily in therapeutic opportunities. The firm is open to investing in any indication area; areas of high interest include precision medicine approaches, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), dermatology and ophthalmology. Generally, the firm is less interested in broad patient populations such as diabetes, Alzheimer’s disease, or cardiovascular disease. The firm generally invests from late preclinical (1-2 years pre-IND) through to Phase II, and prefers to invest in assets with good animal model and/or genetic evidence to support efficacy a3

nd target validation.

The firm only invests in privately held companies. The firm prefers to work with management teams that have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and is therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large not-for-profit healthcare system serves over 2 million people each year has created a strategic investment arm, which launched in 2016 with an inaugural $150M allocation dedicated to investing in innovative companies that fit the healthcare system’s key strategic priorities: safety & quality, analytics, clinical innovations, and technology. The strategic arm focuses on Series A to B funding in innovative companies and will also invest in funds that share the same strategic vision. The firm’s investment sizes typically range from $1-2 million and the firm invests globally. In addition, the firm supports the growth of early-stage companies through an accelerator program.

The firm is focused on personalized health technologies and will consider innovations in medical devices, diagnostics, and healthcare IT/digital health. However, the firm will not invest in therapeutics or Class III (PMA) devices/products. Examples of current investments include a diagnostic company that enables health systems to deliver patient-specific diagnostic and treatment options based on the individual’s DNA, a company developing an automated online platform for patients to better manage their healthcare bills and payments, etc. All technologies must have passed conceptual stage of development and have a valid proof-of-concept.

The firm seek to work with companies that have mitigated technical risk and have achieved initial market validation for their products and technology. The firm will also evaluate companies on the basis of strategic and market fit from a health systems perspective. The firm is a strategic investor and invests in companies in which it intends to use the company’s products or services. The firm has led investment rounds, but generally co-invest with other syndicates. The firm does not always require a board seat in its portfolio companies. The firm’s accelerator program will consider earlier stage companies, including less technical, market and management team development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major health insurance firm has formed a collaborative corporate investment vehicle that is based in the US Midwest. The firm is looking to make investments ranging from $5 – $15 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interest to the payer while also seeking strong financial returns. The firm is actively reviewing new opportunities and will consider companies located around the globe.

The firm is looking to invest in sectors of Healthcare IT, Services, and Diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm is looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com